GL1X · GenesisL1 explorer

MolNFT v1 · #110931 · protein

Type II dasatinib analog crystallized with C-src kinase

4YBJ · Proto-oncogene tyrosine-protein kinase src: “Type II dasatinib analog crystallized with C-src kinase”. X-ray diffraction, 1 ligand (4A9), 5 pockets (best druggability 0.75). MolNFT v1 #110931 on GenesisL1: 3D structure, binding…

PDB
4YBJ
Type
protein
Length
508 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Proto-oncogene tyrosine-protein kinase src
EC
2.7.10.2
UniProt
P00523
Ligands
4A9
Pockets
5 · best druggability 0.75

Structure

x-ray diffraction · 2 distinct chains · 42% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein25544% helix, 17% strandP00523
BProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein25340% helix, 14% strandP00523

Ligands and binding sites

  • 4A9 · 2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-N-(3-{[3-(trifluoromethyl)benzoyl]amino}phenyl)-1,3-thiazole-5-carboxamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17090.750.81674A9
23560.720.84504A9
32730.550.7730empty
41370.370.7325empty
5640.350.7714empty

Interfaces

1 interface between chains.

  • A–B · 358 Ų buried · 5 hydrogen bonds · protein-protein

Compared structures

  • 4YBJ · Type II Dasatinib Analog Crystallized with c-Src Kinase · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.